ProKidney Corp. (NASDAQ:PROK) — Market Cap & Net Worth
Market Cap & Net Worth: ProKidney Corp. (PROK)
ProKidney Corp. (NASDAQ:PROK) has a market capitalization of $376.07 Million ($376.07 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13815 globally and #3319 in its home market, demonstrating a -2.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ProKidney Corp.'s stock price $1.80 by its total outstanding shares 208926941 (208.93 Million). Also see ProKidney Corp. assets under control for a full breakdown of the balance sheet.
ProKidney Corp. Market Cap History: 2021 to 2026
ProKidney Corp.'s market capitalization history from 2021 to 2026. Data shows change from $2.07 Billion to $376.07 Million (-28.15% CAGR). Also see ProKidney Corp. cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
ProKidney Corp. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #376 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1344 of 3165 |
Weight: ProKidney Corp.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ProKidney Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ProKidney Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ProKidney Corp. stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
524.07x
ProKidney Corp.'s market cap is 524.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $353.09 Million | $76.00K | -$61.19 Million | 4645.88x | N/A |
| 2025 | $468.00 Million | $893.00K | -$68.99 Million | 524.07x | N/A |
Competitor Companies of PROK by Market Capitalization
Companies near ProKidney Corp. in the global market cap rankings as of September 18, 2026. Review PROK goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ProKidney Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
ProKidney Corp. Historical Marketcap From 2021 to 2026
Between 2021 and today, ProKidney Corp.'s market cap moved from $2.07 Billion to $ 376.07 Million, with a yearly change of -28.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $376.07 Million | -19.64% |
| 2025 | $468.00 Million | +32.54% |
| 2024 | $353.09 Million | -5.06% |
| 2023 | $371.89 Million | -74.05% |
| 2022 | $1.43 Billion | -30.71% |
| 2021 | $2.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of ProKidney Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $376.07 Million USD |
| MoneyControl | $376.07 Million USD |
| MarketWatch | $376.07 Million USD |
| marketcap.company | $376.07 Million USD |
| Reuters | $376.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more